Ann: Presentation to Investors, page-102

Biotron operates on the smell of oily rag (especially now all trials are completed)… between R&D tax offsets & potential inflows from oppies conversion IMO low chance of further dilution within 12 months. Within this time positive confirmatory trial data to strike a commercial deal. Coming up few months for market to digest incoming trial data from 3 Phase 2 trials… followed by speculation on potential deals coming our way will see SP reach new highs alone. Funny coincidence the other day… Driving out of Brisbane airport while thinking Biotron and checking how SP finished the day.. instantly look up and saw huge giant Gilead Billboard (https://www.gileadhiv.com/) promoting their plans to end HIV epidemic by 2030… coincidence…. looked up their website and Phase II of their initiative starts in 2026 which will expand to address needs across USA with treatment for everyone living with HIV to get correct treatment to achieve VIRAL SUPPRESSION…. Gilead must be watching Biotron very carefully.

All the cards are lining up perfectly.. will it be a royal flush & we add Covid to the mix.. IMO the market totally misunderstood the significance of FDA giving the tick of approval for BIT225 to go straight to Phase II short trial for Covid! BIT225 the wonder drug … HIV… COVID/FLU… & HEP C ??